Interleukin-17

Earlier this month, Healio Dermatology posted a compilation of eight popular reads to kickoff Psoriasis Action Month in psoriasis research, advocacy and FDA news.

Taltz met the primary and secondary endpoints at week 12 in a phase 4 head-to-head study comparing its efficacy and safety vs. Tremfya in patients with moderate to severe plaque psoriasis, according to an announcement from Eli Lilly and Company.